Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06855498 · ClinicalTrials.gov registry record · Phase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
A Phase 3 study of Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT06855498 is a Phase 3 study of Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 600 participants, above the 130-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (362% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT06855498, a Phase 3 study of Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Conditions Studied
Interventions
- DRUG povorcitinib
Study Locations (20)
California
- Investigative Site US076 - Fountain Valley
- Investigative Site US077 - Fremont
- Investigative Site US071 - Huntington Beach
- Investigative Site US020 - Laguna Niguel
- Investigative Site US036 - Los Angeles
- Investigative Site US067 - Los Angeles
- Investigative Site US060 - Northridge
- Investigative Site US037 - Oakland
- Investigative Site US089 - Santa Monica
- Investigative Site US080 - Sherman Oaks
Arizona
- Investigative Site US004 - Phoenix
- Investigative Site US047 - Scottsdale
- Investigative Site US124 - Scottsdale
- Investigative Site US115 - Tucson
Arkansas
- Investigative Site US113 - Fayetteville
- Investigative Site US045 - Fort Smith
- Investigative Site US009 - Rogers
Alabama
- Investigative Site US086 - Birmingham
- Investigative Site US098 - Montgomery
Florida
- Investigative Site US129 - Aventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06855498
The ClinicalTrials.gov registry entry for NCT06855498 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 130-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (362% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 1 intervention - of which povorcitinib is the first listed.
NCT06855498 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06855498 about?
NCT06855498 is a clinical study titled "Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib". Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
What is the current status of trial NCT06855498?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2025-02-28. Estimated completion is 2028-02-28.
What conditions does trial NCT06855498 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT06855498?
The interventions under investigation include: povorcitinib (DRUG).
Who is sponsoring clinical trial NCT06855498?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06855498 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
ACTIVE NOT RECRUITING · Phase 3
-
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
RECRUITING · Phase 2
-
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RECRUITING · Phase 2
-
The Safety and Efficacy of Roflumilast Foam in HS
RECRUITING · Phase 2
-
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
RECRUITING · Early Phase 1
-
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.